Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorder) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas, and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability, or unusual behavior.
The Type 1 Diabetes Drugs in Development market research report provides comprehensive information on the therapeutics under development for Type 1 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes and features dormant and discontinued projects.
What are the targets of the Type 1 Diabetes pipeline drugs market?
Some of the targets of the Type 1 Diabetes pipeline drugs market are Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Glucagon Receptor, Islet Amyloid Polypeptide, and Cannabinoid Receptor 1.
Type 1 Diabetes pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the Type 1 Diabetes pipeline drugs market?
The mechanisms of action of the Type 1 Diabetes pipeline drugs market are Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Cannabinoid Receptor 1 Antagonist, Potassium Voltage Gated Channel Subfamily A Member 3 Blocker, and Sodium/Glucose Cotransporter 2 Inhibitor.
Type 1 Diabetes pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the Type 1 Diabetes pipeline drugs market?
The routes of administration in the Type 1 Diabetes pipeline drugs market are subcutaneous, oral, intravenous, parenteral, intramuscular, inhalational, intradermal, intravitreal, transdermal, and buccal.
Type 1 Diabetes pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the Type 1 Diabetes pipeline drugs market?
The molecule types in the Type 1 Diabetes pipeline drugs market are recombinant peptide, cell therapy, small molecule, monoclonal antibody, synthetic peptide, fusion protein, recombinant protein, gene therapy, gene-modified cell therapy, and vaccine.
Type 1 Diabetes pipeline drugs market, by molecule types
For more molecule types insights, download a free report sample
Which are the key companies in the Type 1 Diabetes pipeline drugs market?
Some of the key companies in the Type 1 Diabetes pipeline drugs market are Novo Nordisk AS, Adocia SAS, Eli Lilly and Co, Akston Biosciences Corp, Biocon Ltd, Merck & Co Inc, Thermalin Inc, Diasome Pharmaceuticals Inc, Algiax Pharmaceuticals GmbH, and Arecor Therapeutics Plc.
Type 1 Diabetes pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
Targets | Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Glucagon Receptor, Islet Amyloid Polypeptide, and Cannabinoid Receptor 1 |
Mechanisms of Action | Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Cannabinoid Receptor 1 Antagonist, Potassium Voltage Gated Channel Subfamily A Member 3 Blocker, and Sodium/Glucose Cotransporter 2 Inhibitor |
Routes of Administration | Subcutaneous, Oral, Intravenous, Parenteral, Intramuscular, Inhalational, Intradermal, Intravitreal, Transdermal, and Buccal |
Molecule Types | Recombinant Peptide, Cell Therapy, Small Molecule, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Recombinant Protein, Gene Therapy, Gene-Modified Cell Therapy, and Vaccine |
Key Companies | Novo Nordisk AS, Adocia SAS, Eli Lilly and Co, Akston Biosciences Corp, Biocon Ltd, Merck & Co Inc, Thermalin Inc, Diasome Pharmaceuticals Inc, Algiax Pharmaceuticals GmbH, and Arecor Therapeutics Plc |
This report provides:
- A snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).
- Reviews of pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Type 1 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.